论文部分内容阅读
Rhesus monkeys were given one MLD of typeA botulismotoxin subcutaneously.Toosendanintherapy was initiated 24 hours after the challenge,with intravenous administration of the drug (0.9-1.0mg/kg)given to 13 monkeys,10 of which recoveredas compared with the survival of only 2 in the12 monkeys of the positive control group.Five of11 monkeys receiving intramuscular Toosendanin sur-vived and recovered;all 6 control monkeys died.Three of 6 monkeys given oral Toosendanin survived,while all 5 positive control monkeys died.The therapeutic effect of Toosendanin on monkeybotulism was evaluated with results showing thatToosendanin given via one of 3 different routes(iv,im and po) has definite therapeutic value in monkeyswith experimental botulism.
Rhesus monkeys were given one MLD of type A botulismotoxin subcutaneously. Toosendanintherapy was initiated 24 hours after the challenge, with intravenous administration of the drug (0.9-1.0 mg / kg) given to 13 monkeys, 10 of which recovered as compared with the survival of only 2 all of the 5 monkeys of the positive control group monkeybotulism was evaluated with results showing that Toosendanin given via one of 3 different routes (iv, im and po) has definite therapeutic value in monkeys with experimental botulism.